drug development — LDV Capital Blog on Visual Technologies and AI — LDV Capital
LDV Blog
Meet Dr. Molly Gibson – Co-Founder and Chief Strategy & Innovation Officer at Generate:Biomedicines, Origination Partner at Flagship Pioneering. LDV Capital's Founder & General Partner Evan Nisselson discussed with Molly how AI and machine learning empower and disrupt the scientific process across life sciences, biotech, advanced materials and more.
If you missed our 10th Annual LDV Vision Summit, this is your chance to watch the video or read our shortened & lightly edited transcript.
As the biotech industry heavily relies on data filtering, analysis, and sharing, visual technologies play a critical role in detecting and imaging biological systems. This paves the way for the future of life sciences tools, enabling next-generation therapeutics, biomanufacturing, and longevity. At our 10th Annual LDV Vision Summit earlier this year, a panel of experts delved into these topics and explored various critical aspects shaping the future of biotechnology. Check out their insights.
On March 21, at our 10th Annual LDV Vision Summit, Evan Nisselson, Founder and General Partner at LDV Capital, will speak with Dr. Molly Gibson – Co-Founder and Chief Strategy and Innovation Officer at Generate:Biomedicines. They will discuss how AI and machine learning empower and disrupt the scientific process across life sciences, biotech, advanced materials, and more. This will have a tremendous impact on business and society.
In the lead-up to the Summit, Evan had the privilege of asking Dr. Gibson a few questions.